Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Redwoods Acquisition Corp. Announces the Separate Trading of its Common Stock, Warrants and Rights, Commencing April 29, 2022
-
Nauticus Robotics to Launch Nauticus Fleet, Pioneering Untethered Robot Teaming for Offshore Industry
-
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
-
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
-
Yotta Acquisition Corporation Announces Closing of $100 Million Initial Public Offering
-
Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022
-
Chardan Acts as M&A and Lead Financial Advisor in Neos sale to Sky
-
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Yotta Acquisition Corporation (YOTAU) Prices 10M Unit IPO at $10/unit
-
Yotta Acquisition Corporation Announces Pricing of $100 Million Initial Public Offering on Nasdaq
-
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
-
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
-
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
-
Senti Bio to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
-
Capstone Green Energy Invited to Participate in Chardan’s Disruptive Tech Leadership Call Series
-
Forge Biologics to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
ProQR Therapeutics N.V. (PRQR) PT Lowered to $2.50 at Chardan Capital Markets
-
CytoImmune to Participate in Upcoming April Investor Conferences
-
Wugen to Participate in Upcoming April Investor Conferences
-
Click Therapeutics to Present at Chardan’s Prescription Digital Therapeutics Summit
-
SQZ Biotechnologies to Present at Upcoming Investor Conferences
-
Caravelle Group Co to Become Publicly Traded via Merger with Pacifico Acquisition Corp. (PAFO)
-
Caravelle Group Co., Ltd, an Ocean Technology and Shipping Company, to Become Publicly Traded via Merger with Pacifico Acquisition Corp.
-
Nauticus Robotics, Inc. Strengthens Management Team with Hiring of Chief Operating Officer
-
Achilles Therapeutics to Present at Upcoming Conferences
-
Pear Therapeutics to Participate in Upcoming Investor Conferences
-
Achilles Therapeutics to Present at Upcoming Conferences
-
Ventoux CCM Acquisition (VTAQ) Announces $1.75M Contribution to Trust Account, Extends Deadline to Consummate Business Combination
-
VENTOUX CCM ACQUISITION CORP. ANNOUNCES ADDITIONAL CONTRIBUTION TO TRUST ACCOUNT TO EXTEND DEADLINE TO CONSUMMATE BUSINESS COMBINATION
-
VENTOUX CCM ACQUISITION CORP. ANNOUNCES ADDITIONAL CONTRIBUTION TO TRUST ACCOUNT TO EXTEND DEADLINE TO CONSUMMATE BUSINESS COMBINATION
-
Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit
-
Redwoods Acquisition Corp. Announces Closing of $100 Million Initial Public Offering
-
Redwoods Acquisition Corp. Announces Closing of $100 Million Initial Public Offering
-
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
-
Redwoods Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering on Nasdaq
-
IPO for SPAC Redwoods Acquisition (RWOD) Opens at $10.05
-
Form X-17A-5 CHARDAN CAPITAL MARKETS For: Dec 31
-
UPDATE: Chardan Capital Markets Starts Silence Therapeutics (SLN) at Buy
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
-
Form 10-K Chardan NexTech Acquisit For: Dec 31
-
Passage Bio to Participate in Upcoming Investor Conferences
-
Passage Bio to Participate in Upcoming Investor Conferences
-
Renovacor Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
-
Medallion Resources Announces Board Changes
-
U.S. step to delist Chinese ADRs worsens investment, listing outlook

